Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman
  
Regenerative medicine developers hope to flourish despite upheaval at US FDA. (Shutterstock)

More from US FDA Performance Tracker

More from Advanced Technologies